MEB Annual report 2013: 50 years of MEB, and beyond

The Medicines Evaluation Board (MEB) has assessed and monitored the efficacy, risks and quality of medicinal products for human and veterinary use for 50 years. The MEB also assesses the safety of novel foods for human consumption. In this annual report, we look back at the developments in 2013.

MEB Chairman Bert Leufkens in the preface recalls the different issues the MEB dealt with, especially in the fields of pharmacovigilance and transparency. He emphasises how the organisation consistently acted in a professional and independent manner. Safeguarding the balance between efficacy and risks takes priority in the work of the MEB.

Executive Director Aginus Kalis describes the steps the organisation took in the past year to conduct its work even better and more efficiently.

CBG Jaarverslag 2013